MINNEAPOLIS--(BUSINESS WIRE)--Sept. 18, 2006--CVRx®, Inc., a private company that has developed an implantable medical device to treat high blood pressure, has named Nadim Yared President and Chief Executive Officer, effective October 4.
CVRx’s flagship product, the Rheos(TM) Baroreflex Hypertension Therapy(TM) System, is intended for use in patients who cannot control their blood pressure with medications and lifestyle modifications. The Rheos System is currently under evaluation in clinical trials in the United States and in Europe.
“This is an exciting time to join CVRx, and I am thrilled for the opportunity to lead it going forward,” said Yared. “The company has a unique product with the potential to address a major unmet medical need. The clinical results to date with Rheos are very promising, and I am optimistic about its future.”
Previously, Yared served as Vice President and General Manager of Medtronic Navigation, the leading supplier of integrated image-guided surgery products in the world. He joined Medtronic Navigation in 2002 after a 10-year career with GE Medical, where he held engineering and marketing management positions of increasing responsibility, including Vice President and General Manager of GE’s European X-ray business. Yared received an engineering degree from Ecole Nationale Superieure des Telecommunications and an M.B.A. degree from Insead in Paris.
Yared will succeed Robert Kieval, a CVRx founder who has served as President and Chief Executive Officer since the company’s inception in 2001. Kieval will continue with CVRx as Executive Vice President and Chief Technology Officer. In that role, he will focus on expanding CVRx’s technology portfolio, identifying new markets for its application and other strategic initiatives.
“I am proud of CVRx’s progress and look forward to working with Nadim,” said Kieval. “He is a seasoned leader in the medical device industry with a strong track record of success. As we expand our product development and advance our clinical trials toward commercialization of the Rheos System, Nadim’s demonstrated capabilities will be invaluable.”
About CVRx: CVRx, Inc. was founded in 2001. The Rheos System is an implantable medical device that is designed to reduce blood pressure by using mild electrical signals to influence the body’s blood pressure regulation system, known as the baroreflex. It is an investigational device and is currently in clinical trials in Europe and the United States. For more information visit www.cvrx.com.
About High Blood Pressure: High blood pressure, also referred to as hypertension, affects about 65 million people in the United States. It is a leading cause of stroke, heart attack, heart failure and kidney disease and is estimated to cause one in every eight deaths worldwide. Approximately 25 percent of people with hypertension cannot control their high blood pressure, despite the use of multiple medications.
CAUTION: CVRx Rheos System is an investigational device and is limited by Federal (or United States) law to investigational use only.
CVRx, Rheos, Baroreflex Hypertension Therapy are trademarks of CVRx, Inc. © CVRx, Inc. 2005
Contact: CVRx, Inc. John Brintnall, 763-416-2853
Source: CVRx
